Bank of Canada Holds Interest Rate at 2.25% Amid Trade and Global Uncertainty 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
U.S. Eases Venezuela Oil Sanctions to Boost American Investment After Maduro Ouster 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
South Korea Industry Minister Heads to Washington Amid U.S. Tariff Hike Concerns 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
Asia Stocks Pause as Tech Earnings, Fed Signals, and Dollar Weakness Drive Markets 
U.S. Stock Futures Edge Lower as Tech Earnings and Fed Decision Shape Market Sentiment 
UK Vehicle Production Falls Sharply in 2025 Amid Cyberattack, Tariffs, and Industry Restructuring 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
Starmer’s China Visit Signals New Era in UK–China Economic Relations 
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 
Asian Currencies Slip as Dollar Rebounds Ahead of Fed Rate Decision 
Google Disrupts Major Residential Proxy Network IPIDEA 
U.S. and El Salvador Sign Landmark Critical Minerals Agreement to Boost Investment and Trade 
UK Housing Market Gains Momentum in Early 2026 as Mortgage Rates Fall 
Samsung Biologics and TG Therapeutics will continue working together as they just renewed their drug manufacturing deal. The contract will allow the South Korean biotechnology firm to produce more drugs for the US-based healthcare company.
The expansion of Samsung Biologics and TG Therapeutics CMO deal
As per The Korea Times, the two companies agreed to sign another deal for the supply of Ublituximab, an investigational monoclonal antibody drug for the treatment of multiple sclerosis. The new contract manufacturing organization (CMO) deal is worth $50.3 million, which is more than double of their previous deal that was only priced at $22.4 million.
This is Samsung Biologics and TG Therapeutics fourth partnership since they teamed up in February 2018. All of their first three contracts were also for the production and supply of Ublituximab.
“We are very glad to be able to flexibly accommodate our client’s expanded needs through our facilities,” Samsung Biologics chief executive officer, John Rim, said in a press release. “By supporting TG Therapeutics in this partnership, we are contributing to bringing needed treatments to patients around the world and getting a step closer to our vision of bringing about a better life for humanity.”
Looking forward to the success of the Ublituximab drug
TG Therapeutics has been developing Ublituximab for a while now, and the company already requested for biologics license by submitting an application to the U.S. Food and Drug Administration (FDA). The said drug is in the third phase of testing, so it is crucial for the license to be approved.
In any case, Samsung Biologics mainly provides manufacturing, development, and testing services to its clients. The company helps them meet the demand through CMO deals, and as it continues to receive new contracts, it is now building its fourth manufacturing plant in Incheon, and so far, this will be the Samsung Biologics’ largest facility.
Meanwhile, once TG Therapeutics finally received its license and its drug development for Ublituximab is successful, Samsung Biologics is reportedly guaranteed a minimum contract worth $278.1 million. This price can potentially go up to $345.6 million if the American healthcare firm makes more drugs.
"Samsung is the global leader in biologics manufacturing and we are happy to have them as our partner as we look forward to the potential commercialization of Ublituximab across both oncology and autoimmune indications," Michael S. Weiss, TG Therapeutics CEO, said.
